JP2025502061A5 - - Google Patents

Info

Publication number
JP2025502061A5
JP2025502061A5 JP2024540882A JP2024540882A JP2025502061A5 JP 2025502061 A5 JP2025502061 A5 JP 2025502061A5 JP 2024540882 A JP2024540882 A JP 2024540882A JP 2024540882 A JP2024540882 A JP 2024540882A JP 2025502061 A5 JP2025502061 A5 JP 2025502061A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
bispecific antibody
muc16
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/010326 external-priority patent/WO2023133280A1/en
Publication of JP2025502061A publication Critical patent/JP2025502061A/ja
Publication of JP2025502061A5 publication Critical patent/JP2025502061A5/ja
Pending legal-status Critical Current

Links

JP2024540882A 2022-01-07 2023-01-06 再発性卵巣癌を、二重特異性抗muc16×抗cd3抗体単独で、または抗pd-1抗体と組み合わせて治療する方法 Pending JP2025502061A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263297333P 2022-01-07 2022-01-07
US63/297,333 2022-01-07
US202263342542P 2022-05-16 2022-05-16
US63/342,542 2022-05-16
US202263394483P 2022-08-02 2022-08-02
US63/394,483 2022-08-02
US202263421541P 2022-11-01 2022-11-01
US63/421,541 2022-11-01
PCT/US2023/010326 WO2023133280A1 (en) 2022-01-07 2023-01-06 Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (2)

Publication Number Publication Date
JP2025502061A JP2025502061A (ja) 2025-01-24
JP2025502061A5 true JP2025502061A5 (cg-RX-API-DMAC7.html) 2026-06-10

Family

ID=85199214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540882A Pending JP2025502061A (ja) 2022-01-07 2023-01-06 再発性卵巣癌を、二重特異性抗muc16×抗cd3抗体単独で、または抗pd-1抗体と組み合わせて治療する方法

Country Status (9)

Country Link
US (1) US20230312718A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460520A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502061A (cg-RX-API-DMAC7.html)
KR (1) KR20240130137A (cg-RX-API-DMAC7.html)
AU (1) AU2023204751A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242629A1 (cg-RX-API-DMAC7.html)
IL (1) IL313864A (cg-RX-API-DMAC7.html)
MX (1) MX2024008055A (cg-RX-API-DMAC7.html)
WO (1) WO2023133280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
TW202542187A (zh) * 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法

Similar Documents

Publication Publication Date Title
TWI890661B (zh) 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
EP3986569A1 (en) Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
JP2023505218A5 (cg-RX-API-DMAC7.html)
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
JP2019503361A (ja) がんを治療するための抗pd−1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
JP2021528423A5 (cg-RX-API-DMAC7.html)
WO2020063988A1 (zh) Cldn18的抗体和化疗药物的联合治疗
CN105377894A (zh) 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
JP2022512851A5 (cg-RX-API-DMAC7.html)
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP2025509567A (ja) 再発性類上皮肉腫を、二重特異性抗MUC16x 抗CD3抗体単独で、または抗PD-1抗体と組み合わせて治療する方法
JP2025517336A5 (cg-RX-API-DMAC7.html)
JP2022520572A5 (cg-RX-API-DMAC7.html)
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
RU2024122332A (ru) СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО РАКА ЯИЧНИКА С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХ АНТИТЕЛ К MUC16 x CD3 ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
RU2024129390A (ru) СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1
US20220389088A1 (en) Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
WO2025056011A1 (zh) 包含抗pd-1抗体和第二抗体的药物组合物
CN116615238A (zh) 用于治疗癌症和减轻细胞因子释放综合征的抗体组合
JP2025508832A5 (cg-RX-API-DMAC7.html)
JP2021518393A5 (cg-RX-API-DMAC7.html)
CN115607663A (zh) 抗pd-1抗体在治疗原发纵隔大b细胞淋巴瘤中的应用
RU2022101756A (ru) Антитела к tigit и их применение